Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. The company has collaboration with the Centre for Continuous Manufacturing and Advanced Crystallisation at the University of Strathclyde to support the scale-up and characterisation of Nuvec. The company was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026. Thalia Therapeutics Plc was incorporated in 1979 and is based in London, the United Kingdom.…
Thalia Therapeutics (LSE:THAT) Shares Interim Progress
Thalia Therapeutics CEO discusses early clinical progress with AML therapeutic miRisten
Thalia Therapeutics (LON: THAT) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 0.5750 GBp on 20 November 2026, down 8.0% over 52 weeks. Its 52-week range is 0.4000 GBp to 0.9500 GBp: the price is 39.5% below the high and 43.7% above the low.
Its market capitalisation is 10.21M GBP.
Thalia Therapeutics reports return on equity of -112.6% and revenue down 1.3% year over year.
It holds more cash than debt, a net cash position of 1.50M GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.